It looks like the first truly effective weight loss drug has arrived. Learn the basic facts about semaglutide and get perspectives from Milton Packer and Sanjay Kaul on what lies ahead.
Trials in Heart Failure with Preserved Ejection Fraction: An Interview with Steve Nissen and Milton Packer
Faiez Zannad moderates a fascinating discussion between Milton Packer and Steve Nissen about the PARAGON-HF trial in heart failure with preserved ejection fraction. Nissen was…
A Brand New Drug for Heart Failure with Reduced Ejection Fraction: An Interview with Javed Butler about Vericiguat
Faiez Zannad speaks to Javed Butler about the FDA approval of new drug, vericiguat, for heart failure with reduced ejection fraction, following the publication of…
Global Trials Summit 2021: An Interview with John McMurray
Faiez Zannad speaks to John McMurray about the Global Trials Summit being held virtually on 12th and 13th February 2021. Register here : https://global-trials-summit.hubilo.com/
Chunkification of Clinical Trials: Why aren’t we adopting the Win Ratio more widely?
Most of us like our news (medical or otherwise) pre-digested into understandable chunks for consumption. This need for this is inevitable because we expect to…
CVCT Forum 2020: An Interview with John Teerlink about Omecamtiv
What’s unique about omecamtiv? Darrel Francis speaks to GALACTIC-HF PI, John Teerlink about that dirty word in heart failure… “inotrope”. The new language is myotropes,…
CVCT Forum 2020: An Interview with Paul Armstrong about Vericiguat
Darrel Francis speaks to Paul Armstrong, PI of the VICTORIA trial, about the mechanism of new heart failure drug, Vericiguat, and the trial’s unusual power calculation: “The trial was deliberately overpowered on the primary endpoint”.
Charlie and the Medicine Factory (Do we really need to understand mechanisms?)
One of my favorite books growing up was “Charlie and the Chocolate Factory”. I revelled in the comeuppance meted out to the likes of Augustus…
CVCT Forum Teaser 2020: SGLT2 inhibitor trials in CKD
SGLT2 inhibitors are probably the hottest new drug on the scene in cardiology this year. They were bandied about for lowering glucose in diabetes but…